$APTN

ADAPTIN BIO, INC.

CIK:0001938571|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating Expenses:
Research and development	$ 138,167	$ 340,334	$ 303,744	$ 402,467
General and administrative	1,062,449	1,180,521	2,041,025	1,968,846
Total Operating Expenses	1,200,616	1,520,855	2,344,769	2,371,313
Loss from Operations	(1,200,616)	(1,520,855)	(2,344,769)	(2,371,313)
Other Expense (Income):
Interest expense	4,696		6,639	72,659
Loss on change in fair value of derivative liabilities				6,312
Gain on extinguishment of debt				(326,345)
Total Other Expense (Income), net	4,696		6,639	(247,374)
Loss before provision for income taxes	(1,205,312)	(1,520,855)	(2,351,408)	(2,123,939)
Provision for income taxes
Net loss	$ (1,205,312)	$ (1,520,855)	$ (2,351,408)	$ (2,123,939)
Net Loss Per Share
Basic (in Dollars per share)	$ (0.14)	$ (0.18)	$ (0.27)	$ (0.3)
Diluted (in Dollars per share)	$ (0.14)	$ (0.18)	$ (0.27)	$ (0.3)
Weighted Average Common Shares Outstanding:
Basic (in Shares)	8,849,266	8,454,634	8,775,964	7,148,094
Diluted (in Shares)	8,849,266	8,454,634	8,775,964	7,148,094

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows From Operating Activities:
Net loss	$ (2,351,408)	$ (2,123,939)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt issuance costs and discounts		53,722
Change in fair value of derivative liabilities		6,312
Gain on extinguishment of debt		(326,345)
Stock-based compensation	539,202
Shares issued in exchange for services	250,000	250,000
Changes in operating assets and liabilities:
Prepaid expenses	182,126	(299,661)
Accounts payable - trade	119,494	(348,611)
Accrued expenses	214,124	(528,254)
Accrued interest		14,190
Net Cash Used In Operating Activities	(1,046,462)	(3,302,586)
Cash Flows From Financing Activities:
Repayment of financing liability	(170,897)
Repayment of notes payable- related party		(275,000)
Proceeds from issuance of common stock pursuant to warrant exercises	669,106
Proceeds from issuance of common stock in private placement	912,000
Proceeds from issuance of common stock and warrants in private placement		6,161,505
Payment of issuance costs related to private placement	(152,433)	(1,266,485)
Net Cash Provided By Financing Activities	1,257,776	4,620,020
Net Increase In Cash and Cash Equivalents	211,314	1,317,434
Cash and Cash Equivalents - Beginning of Period	459,174	34,085
Cash and Cash Equivalents - End of Period	670,488	1,351,519
Supplemental Disclosures of Cash Flow Information:
Interest	6,639	9,584
Income taxes
Non-cash investing and financing activities:
Recapitalization of Unite Acquisition 1 Corp. accumulated deficit at time of the exchange		(279,746)
Common stock cancelled at the time of the exchange		175
Convertible notes and accrued interest converted into common stock		1,653,811
Forgiveness of accrued consulting fees by related parties		345,900
Equity issuance costs included within accounts payable	42,421
Financing of Director and Officer insurance policy	$ 333,105

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets:
Cash and cash equivalents	$ 670,488	$ 459,174
Prepaid expenses and other current assets	310,964	159,985
Total Current Assets	981,452	619,159
Total Assets	981,452	619,159
Current Liabilities:
Accounts payable - trade	1,674,005	1,512,090
Accrued expenses	810,589	596,465
Financing liability	162,208
Total Current Liabilities	2,646,802	2,108,555
Total Liabilities	2,646,802	2,108,555
Commitments and contingencies (Note 12)
Stockholders’ Deficit:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 50,000,000 shares authorized; 9,053,279 and 8,655,829 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	905	866
Additional paid-in capital	9,976,954	7,801,539
Accumulated deficit	(11,643,209)	(9,291,801)
Total Stockholders’ Deficit	(1,665,350)	(1,489,396)
Total Liabilities and Stockholders’ Deficit	$ 981,452	$ 619,159